Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 13, Issue 12, Pages 3020-3032Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2017.1383575
Keywords
Vaccines; viral vectors; MERS Co-V; Lassa fever; Nipah
Categories
Funding
- Wellcome Trust [104750/Z/14/Z] Funding Source: Wellcome Trust
- National Institute for Health Research [NF-SI-0514-10158] Funding Source: researchfish
- Wellcome Trust [104750/Z/14/Z] Funding Source: researchfish
Ask authors/readers for more resources
The 2014-15 Ebola outbreak in West Africa highlighted the potential for large disease outbreaks caused by emerging pathogens and has generated considerable focus on preparedness for future epidemics. Here we discuss drivers, strategies and practical considerations for developing vaccines against outbreak pathogens. Chimpanzee adenoviral (ChAd) vectors have been developed as vaccine candidates for multiple infectious diseases and prostate cancer. ChAd vectors are safe and induce antigen-specific cellular and humoral immunity in all age groups, as well as circumventing the problem of pre-existing immunity encountered with human Ad vectors. For these reasons, such viral vectors provide an attractive platform for stockpiling vaccines for emergency deployment in response to a threatened outbreak of an emerging pathogen. Work is already underway to develop vaccines against a number of other outbreak pathogens and we will also review progress on these approaches here, particularly for Lassa fever, Nipah and MERS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available